Free Trial
→ Elon Just Fired the IRS Agents Targeting Your Savings (From Priority Gold) (Ad) Free ELVN Stock Alerts

Enliven Therapeutics (ELVN) SEC Filings & 10K Form

Enliven Therapeutics logo
$21.95 -0.40 (-1.79%)
Closing price 04:00 PM Eastern
Extended Trading
$21.86 -0.09 (-0.39%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

Recent Enliven Therapeutics SEC Filings

Export to Excel
DateFilerForm TypeView
07/23/2025
5:52 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/21/2025
6:21 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2025
6:54 PM		BlackRock, Inc. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form SCHEDULE 13G/A
07/17/2025
3:13 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/14/2025
4:07 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/09/2025
6:29 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/07/2025
3:15 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/01/2025
3:42 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2025
3:05 PM		Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/24/2025
4:36 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025
5:22 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025
4:30 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
ORBIMED ADVISORS LLC (Filed by)
Form SCHEDULE 13D/A
06/17/2025
3:24 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2025
5:44 AM		Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/13/2025
8:39 PM		Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 424B5
06/13/2025
5:17 AM		Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 424B5
06/13/2025
5:26 AM		Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form S-3MEF
06/13/2025
5:05 AM		Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2025
5:25 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025
3:21 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/05/2025
3:53 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025
3:55 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025
4:34 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/03/2025
4:14 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/29/2025
4:38 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025
5:29 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025
5:31 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2025
3:21 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/19/2025
3:22 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/09/2025
5:48 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2025
5:42 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2025
5:43 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/30/2025
5:59 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2025
3:08 PM		Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form DEFA14A
04/28/2025
3:12 PM		Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form ARS
04/21/2025
4:55 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/09/2025
3:25 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2025
3:09 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/31/2025
6:37 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2025
3:01 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/26/2025
6:37 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Trump’s Endgame? (R.I.P. China) (Ad)

Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trillion U.S. manufacturing boom. Dubbed Trump’s “New Golden Age” tech, this breakthrough has drawn praise from Elon Musk and NVIDIA’s CEO—and early investors may have a rare chance to get in ahead of the crowd.

See why this could be the biggest shift in manufacturing in decades
03/21/2025
4:49 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/19/2025
4:42 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/19/2025
3:18 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/18/2025
4:33 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144/A
03/18/2025
4:22 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144/A
03/18/2025
3:06 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/17/2025
3:14 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/13/2025
4:05 PM		Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/07/2025
3:18 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/06/2025
5:02 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
7:07 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/27/2025
3:10 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/14/2025
4:02 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/14/2025
2:45 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Fairmount Funds Management LLC (Filed by)
Form SCHEDULE 13G/A
02/14/2025
8:17 AM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Polar Capital Holdings Plc (Filed by)
Form SCHEDULE 13G/A
02/10/2025
4:36 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Gupta Rishi (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:38 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:39 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kunkel Lori Anne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:40 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Phillips Andrew John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:25 PM		Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:27 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:28 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:29 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:32 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:33 PM		Ballal Rahul D. (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:34 PM		Bauer Jake (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/10/2025
4:35 PM		Derynck Mika K (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/07/2025
6:06 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/29/2025
6:21 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
3:37 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/14/2025
3:06 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/14/2025
3:01 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/10/2025
4:31 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
3:43 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
3:21 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/31/2024
4:18 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/27/2024
3:33 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/16/2024
3:15 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/02/2024
4:18 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/15/2024
3:28 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2024
4:46 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13G/A
11/14/2024
4:48 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
Form SC 13G/A
11/14/2024
3:24 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form SC 13G/A
11/13/2024
4:55 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Polar Capital Holdings Plc (Filed by)
Form SC 13G
11/13/2024
3:15 PM		Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/08/2024
1:17 PM		BlackRock, Inc. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form SC 13G
10/30/2024
5:04 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2024
1:02 PM		BlackRock, Inc. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Form SC 13G
10/22/2024
3:18 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:19 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Trump’s Endgame? (R.I.P. China) (Ad)

Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trillion U.S. manufacturing boom. Dubbed Trump’s “New Golden Age” tech, this breakthrough has drawn praise from Elon Musk and NVIDIA’s CEO—and early investors may have a rare chance to get in ahead of the crowd.

See why this could be the biggest shift in manufacturing in decades
10/22/2024
3:21 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:22 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:23 PM		Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:17 PM		Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/18/2024
5:42 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:27 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:42 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:10 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
4:17 PM		Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)


Related Companies and Tools

Related Companies
SEC Filings Tools

This page (NASDAQ:ELVN) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Treasury Secretary Bessent Is Betting Big on Gold
When the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...
Golden Portfolio | Sponsored
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...
Brownstone Research | Sponsored
FREE GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
GoldCo Precious Metals | Sponsored
Buffett to put 90% of his money in this one stock?
CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...
Altimetry | Sponsored
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
Critical AI announcement set to ignite AI 2.0
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored